Bionic Plus back on vet clinic shelves
A long-acting, controlled- release capsule designed to protect ewes from internal parasites during the lambing period is back on the market following a comprehensive reassessment.
Boehringer Ingelheim says it will stop manufacturing locally-produced livestock ruminant products in New Zealand by late 2022 - ending more than 50 years of local production.
The animal health company says it will cease production from its Auckland site from December 2022. It says it will deliver a more 'targeted' range of cattle and sheep products, including brands such as Eprinex, Eclipse and Bionic Plus. However, the company adds that some of these products will be produced locally by contract manufacturing partners in New Zealand.
Meanwhile, the company says it will continue to distribute therapeutic medicines such as Metacam, Bivatop and Mamyzin - along with its range of swine vaccines and companion animal products, such as NexGard and Broadline.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with a presence in more than 150 countries.
NZ country manager Steve Rochester says the company will work with veterinarians, farmers and stakeholders across New Zealand through to December 2022. He is promising to deliver a comprehensive business support plan to help with the transition.
"Boehringer Ingelheim, and before that Merial Ancare, has been an integral member of the New Zealand animal health industry for over 50 years," Rochester says.
"We recognise this announcement is a significant change for members of the Boehringer Ingelheim team, farmers, veterinarians and the wider agricultural industry."
He says the company wanted to communicate the decision as early as possible to ensure those affected have the time to consider what this change means for them.
"Our team will be partnering closely with our customers and industry stakeholders over the coming months and will continue to share information as decisions are made," Rochester adds.
"We want to reassure our customers that we will work closely with them to provide ongoing business support and meet their product requirements during this transition period."
He adds that the company will continue to produce and supply its full range of livestock products and deliver on commercial agreements over the coming year.
He adds that Boehringer Ingelheim will continue to invest in the research and development of new breakthrough therapies for the health and wellbeing of animals.
"For many decades, Boehringer Ingelheim has provided New Zealand farmers and pet owners innovative medicines, products and services to support the health and wellbeing of their animals," says Rochester.
"We are committed to building on those strong partnerships and provide innovative animal health solutions into the future."
Farmers appear to be backing the Government's recent Resource Management Act (RMA) reforms announcement.
For the first time, all the big names in agricultural drone technology are being brought together under one marquee at the National Fieldays.
Fonterra has announced an improved third quarter performance – with a profit after tax of $1.15 billion, up $119 million on the same period last year.
The Fieldays Innovation Awards competition has attracted a diverse and impressive array of innovations from across the primary industries, highlighting the growing importance of technology shaping the future of farming.
Coming to the fore following the carnage of Cyclone Gabrielle, Starlink became well known for providing internet access even in NZ's most inaccessible places.
From this winter farmers will have a greater choice of feed types and blend options than ever before, thanks to Farmlands' purchase of animal nutrition company SealesWinslow.
OPINION: Imagine if the Hound had called the Minister of Finance the 'c-word' and accused her of "girl math".
OPINION: It's good news that Finance Minister Nicola Willis has slashed $1.1 billion from new spending, citing "a seismic global…